MiR-21: Clinical trial started

Regulus began the international ATHENA study to characterize the natural decline of renal function markers, such as glomerular filtration rate (GFR), creatinine, proteinuria and beta-2 microglobulin, in about 120 patients aged >=16 years with Alport syndrome. The study aims to inform the design of a Phase II trial to evaluate RG-012 to treat Alport syndrome, a genetic kidney disease characterized by end-stage kidney disease and hearing loss. ...